Every major cardiovascular guideline in the world continues to recommend statins for eligible patients despite clear evidence that these drugs modestly raise the risk of developing type 2 diabetes. A large individual-participant-data meta-analysis published in The Lancet Diabetes & Endocrinology found that low-to-moderate-intensity statin therapy increases new diabetes diagnoses by about 10%, while high-intensity therapy raises it by roughly 36%, compared with placebo. That sounds alarming in isolation, but the same body of evidence consistently shows that the cardiovascular benefits of statins dwarf the diabetes hazard. Understanding how guidelines navigate this tradeoff, and what it means for you personally, requires looking at the numbers more carefully.
How Large Is the Diabetes Risk, in Real Terms?
Relative risk numbers like “36% increase” can be misleading without context. In the Lancet meta-analysis, high-intensity statin users developed diabetes at a rate of about 4.8% per year versus 3.5% per year in the placebo group. For low-to-moderate-intensity therapy, the rates were 1.3% per year on a statin versus 1.2% on placebo. In absolute terms, the extra risk from intensive therapy works out to roughly 2 additional cases of diabetes per 1,000 patients per year, with a number needed to harm of about 498 per year.1PubMed Central. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis2JAMA. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis So for every 498 people taking a high-intensity statin for a year, you would expect one extra person to be diagnosed with diabetes who would not have been diagnosed otherwise. That is a real risk, but it is small in absolute terms.
It also appears that statins accelerate the arrival of diabetes rather than causing it from scratch. In the JUPITER trial, which tested rosuvastatin in primary prevention, statin allocation moved the average time to diabetes diagnosis forward by just over five weeks compared with placebo. Most of the people who developed diabetes on the statin already had pre-existing metabolic risk factors that made a future diagnosis likely anyway.3PubMed Central. Cardiovascular Benefits and Diabetes Risks of Statins in Primary Prevention
Who Is Most Vulnerable?
Not everyone on a statin faces the same diabetes risk. The people most susceptible are those who are already partway down the road toward metabolic disease. Pre-existing risk factors like obesity, metabolic syndrome, elevated fasting glucose, raised triglycerides, high blood pressure, and elevated HbA1c all amplify the chance of a statin tipping someone into a diabetes diagnosis.4PubMed Central. Statins and risk of type 2 diabetes: mechanism and clinical implications Age also matters; older adults have consistently shown higher rates of statin-associated new-onset diabetes in clinical trials.5PubMed Central. Statin use and risk of diabetes mellitus
In the JUPITER analysis, participants who had at least one major diabetes risk factor at enrollment were 28% more likely to develop diabetes on rosuvastatin than on placebo. But those with no major risk factors had no increased diabetes at all: the hazard ratio was 0.99.6PubMed Central. Cardiovascular Benefits and Diabetes Risks of Statins in Primary Prevention This is a critical point for risk communication. If you are metabolically healthy, the diabetes signal from statins is essentially absent. If you are already carrying metabolic baggage, the drug may push you across the diagnostic threshold sooner than you would have arrived on your own.
Why the Cardiovascular Benefit Still Wins
Guidelines do not ignore the diabetes risk. They weigh it against what statins deliver on the cardiovascular side, and the math is not close. In the JUPITER trial among participants with diabetes risk factors, for every 54 new cases of diabetes diagnosed, 93 vascular events or deaths were prevented. Even among those who did develop diabetes while taking the statin, the cardiovascular benefit persisted: the hazard ratio for cardiovascular events in that subgroup was 0.63, similar to the overall trial result.7PubMed Central. Cardiovascular Benefits and Diabetes Risks of Statins in Primary Prevention
A large 2025 propensity-matched study examining statin use in primary prevention confirmed this pattern in real-world data. Even though statin therapy was associated with higher rates of incident type 2 diabetes, the final cardiovascular risk among those who developed diabetes on the statin remained lower than the threshold that would have warranted statin prescription in the first place.8PubMed Central. Statin-induced risk of diabetes does not reduce cardiovascular benefits in primary prevention: a 6-year propensity-score matched study in a large population In other words, the lipid-lowering benefit more than compensated for the metabolic hit.
Meta-analyses pooling data from over 18,000 people with diabetes across 14 randomized statin trials showed a 9% reduction in all-cause mortality and a 13% reduction in vascular mortality for each 1 mmol/L drop in LDL cholesterol.9Diabetes Care. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024 The survival benefit is substantial and consistent, and it extends to people who already have diabetes.
What the Major Guidelines Actually Recommend
The major guideline bodies all land in roughly the same place: statins remain first-line therapy for cardiovascular risk reduction, with the diabetes risk acknowledged as a manageable side effect rather than a reason to withhold treatment. The specifics differ by patient group.
The 2018 AHA/ACC multi-society cholesterol guidelines recommend moderate-intensity statin therapy for people with diabetes aged 40 to 75 years as a starting point. For those who are older, have higher estimated cardiovascular risk, or have additional risk-enhancing factors, high-intensity therapy is preferred after a shared decision-making discussion. In people with diabetes who already have established atherosclerotic cardiovascular disease, high-intensity statin therapy is recommended outright.10PubMed. The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes
The American Diabetes Association’s 2024 Standards of Care echo this structure. For people with diabetes aged 40 to 75 without cardiovascular disease, moderate-intensity statin therapy is recommended alongside lifestyle measures. When one or more additional cardiovascular risk factors are present, the recommendation escalates to high-intensity statin treatment with a goal of reducing LDL cholesterol by at least 50% from baseline and targeting an LDL below 70 mg/dL. For people of all ages who have both diabetes and established cardiovascular disease, high-intensity statin therapy is standard.11Diabetes Care. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
In Europe, the 2025 focused update of the ESC/EAS dyslipidaemia guidelines recommends using the SCORE2-Diabetes algorithm to estimate 10-year cardiovascular risk in people with type 2 diabetes who do not already have cardiovascular disease, then matching statin intensity to the estimated risk level.12European Heart Journal. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias All three guideline systems share the same fundamental message: statins are not optional extras for cardiovascular risk management in diabetes. The diabetes-risk side effect does not change that calculation.
Which Statins Carry More or Less Risk?
Not all statins are equal here. A large population-based Canadian study compared diabetes incidence across individual molecules, using pravastatin as the reference. Atorvastatin carried about a 22% higher hazard for new-onset diabetes than pravastatin, rosuvastatin about 18% higher, and simvastatin about 10% higher. Fluvastatin and lovastatin showed no significant increase.13BMJ. Risk of incident diabetes among patients treated with statins: population based study A network meta-analysis of different types and doses confirmed that pravastatin 40 mg/day had the lowest diabetes risk compared with placebo, while rosuvastatin 20 mg/day had the highest point estimate, with atorvastatin 80 mg/day falling in between.14PubMed. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus
Pitavastatin is often mentioned as a potentially diabetes-neutral option, and some narrative reviews group it with pravastatin as carrying lower metabolic risk.15PubMed Central. Statin Induced New-onset Diabetes Mellitus – A Narrative Review The practical reality is that most people are prescribed atorvastatin or rosuvastatin because these are the high-intensity options with the strongest cardiovascular evidence base. Switching to a lower-risk molecule sometimes means accepting weaker LDL lowering, which is a tradeoff that has to be weighed individually.
Dose matters too. In a Korean nationwide cohort study of patients after heart attacks, the high-intensity statin group had a diabetes incidence of 7.8% versus 5.8% in the moderate-intensity group, and high-intensity use was an independent predictor of new-onset diabetes.16Scientific Reports. Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study One strategy gaining traction is combining a moderate-intensity statin with ezetimibe, a non-statin cholesterol drug, to achieve the same LDL reduction with a lower diabetes cost. A study of patients after coronary stenting found that moderate-intensity statin plus ezetimibe reduced new diabetes diagnoses to 10.7% compared with 12.5% on high-intensity statin alone, with similar cardiovascular outcomes.17PubMed Central. Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention
How Statins Affect Blood Sugar Mechanically
Statins raise blood sugar through at least two separate routes, one involving insulin production and the other involving how your muscles respond to insulin.
On the insulin production side, statins interfere with beta cells in the pancreas, the cells responsible for making insulin. The drug’s core job is blocking an enzyme in the cholesterol-making pathway, but that same pathway produces molecules the beta cells depend on for normal function. When those molecules are depleted, the beta cells become less able to sense glucose and release insulin in response. Lab studies show that lipophilic statins like simvastatin dramatically reduce glucose-stimulated insulin secretion, while more water-soluble statins like pravastatin have little effect.18PLoS ONE. Simvastatin Impairs Insulin Secretion by Multiple Mechanisms in MIN6 Cells Atorvastatin has been shown to disrupt signaling inside islet cells by depleting a key intermediate called geranylgeranyl pyrophosphate, which in turn reduces the functional mass of insulin-producing cells.19PubMed. Atorvastatin Targets the Islet Mevalonate Pathway to Dysregulate mTOR Signaling and Reduce β-Cell Functional Mass Statins also reduce levels of coenzyme Q10, a molecule used in cellular energy production, which can further impair insulin release.20Diabetes & Metabolism Journal. Diabetogenic Effect of Statins: A Double-Edged Sword?
On the insulin resistance side, statins interfere with glucose uptake in muscle tissue. Normally, insulin triggers a signaling chain that moves glucose transporter proteins to the cell surface so sugar can enter the cell. Simvastatin has been shown to disrupt this chain in skeletal muscle, reducing the phosphorylation of key signaling proteins and impairing the movement of glucose transporters to cell membranes.21PubMed. Mechanisms of insulin resistance by simvastatin in C2C12 myotubes and in mouse skeletal muscle22PubMed. Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3β phosphorylation Research in human muscle cells suggests that long-term statin exposure can permanently redirect the cell toward an alternative energy pathway while blocking the insulin-dependent one, producing a kind of metabolic inflexibility that contributes to insulin resistance over time.23PubMed Central. Statins Aggravate the Risk of Insulin Resistance in Human Muscle
If You Already Have Diabetes
Statins do not just raise the risk of developing diabetes in people who do not have it. They also modestly worsen blood sugar control in people who already do. A systematic review and meta-analysis of nine trials found that people with diabetes randomized to statins had an HbA1c about 0.12 percentage points higher on average than those on placebo, over a mean follow-up of three and a half years.24PubMed. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis A further meta-analysis found that the glycaemic worsening was more pronounced with more aggressive LDL-lowering regimens and at lower target LDL levels.25PubMed. Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis
In the CARDS trial, which tested atorvastatin specifically in people with type 2 diabetes, glycaemia progression (meaning a worsening of blood sugar over time) occurred in about 78% of patients on the statin compared with 74% on placebo. The average treatment effect on HbA1c was a 0.14 percentage point increase. Importantly, this effect did not get worse with time, and it did not erode the cardiovascular benefit: atorvastatin’s protection against cardiovascular events was the same regardless of how a person’s HbA1c changed during the trial.26PubMed Central. Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)
The practical takeaway for people with diabetes is that your doctor may need to adjust your glucose-lowering medications slightly after starting a statin, but the statin itself remains essential for reducing your cardiovascular risk, which is the leading cause of death in people with diabetes.
Can Lifestyle Changes Offset the Effect?
This is a question many patients and clinicians ask, and the honest answer is: partially, but probably not completely. Data from the Diabetes Prevention Program, which tested intensive lifestyle intervention against metformin for diabetes prevention, found that statin use was associated with a 36% higher risk of incident diabetes regardless of which treatment arm people were in.27Diabetes Care. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program The statin risk appeared to operate on top of whatever else was happening, whether that was intensive diet and exercise or metformin.
A Finnish study of people at high risk for diabetes found a similar pattern. Despite receiving lifestyle counseling, statin users had a small but measurable rise in fasting glucose over a year that non-users did not, even after adjusting for age, weight, and other medications.28BMJ Open. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project This does not mean lifestyle changes are useless in statin users. Exercise and weight management still dramatically reduce overall diabetes risk and improve insulin sensitivity. They just may not fully neutralize the specific metabolic push that statins exert through the mechanisms described earlier.
Emerging Alternatives and Combination Strategies
If the diabetes risk from statins is driven by the drug’s interference with the cholesterol-synthesis pathway inside beta cells and muscle tissue, then lipid-lowering drugs that work through different mechanisms might avoid the problem. The evidence so far supports this idea. Ezetimibe, which blocks cholesterol absorption in the intestine, and bempedoic acid, which inhibits an enzyme upstream of the one statins target but operates in the liver rather than in muscle or pancreatic tissue, both appear to lower LDL without the diabetes signal seen with statins.29PubMed Central. New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
As mentioned earlier, combining a moderate-intensity statin with ezetimibe can match the LDL lowering of high-intensity statin monotherapy while producing fewer new diabetes cases.30PubMed Central. Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention This approach is not yet the default in guidelines, but it is increasingly discussed as a way to thread the needle for patients at high metabolic risk who need aggressive LDL reduction.
The Adherence Problem
One of the most consequential real-world effects of the statin-diabetes link has nothing to do with biology. When the FDA added a diabetes warning to statin labels in 2012, concerns about side effects became another reason for patients to stop taking their medication or refuse to start. Statin non-adherence is already a major public health problem, and fear of developing diabetes adds to the list of reasons people give for discontinuing.31PubMed Central. How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy? The irony is that skipping a statin to avoid a modest diabetes risk dramatically increases your cardiovascular risk, which is far more dangerous in the near term. A heart attack or stroke is a more immediate and more serious threat than a slightly earlier diabetes diagnosis, especially one that can be monitored and managed.
If you are concerned about the diabetes risk of your statin, the productive conversation with your doctor is not whether to stop the statin. It is about whether you can achieve the same cardiovascular protection at a lower metabolic cost, through a dose adjustment, a molecule switch, or adding a non-statin agent to allow a step-down in statin intensity.
Genetics and the Future of Personalized Risk
Researchers are beginning to explore whether genetic variation can identify who is most likely to develop diabetes on a statin. The gene HMGCR, which codes for the enzyme that statins inhibit, is an obvious candidate. A recent study found that certain haplotype combinations in the HMGCR gene were associated with a significantly lower risk of new-onset diabetes in statin users, though the associations were modest and some did not survive correction for multiple testing.32PubMed Central. HMGCR genetic variation and risk of new-onset type 2 diabetes in statin users Other work has shown that HMGCR variants also influence how well statins lower cholesterol in people with diabetes, adding another layer to the pharmacogenomic picture.33Pharmacogenetics and Genomics. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study
This field is still too young to change clinical practice. No guideline currently recommends genetic testing before prescribing a statin. But the direction of travel is clear: within the next decade, it may be possible to look at someone’s genotype and say with more confidence whether they are the kind of patient who can tolerate a high-intensity statin without metabolic consequences, or whether a combination strategy would serve them better from the start.